

FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP

600 CONGRESS AVENUE, SUITE 2400

AUSTIN, TEXAS 78701

TELEPHONE: 512/474-5201
FACSIMILE: 512/536-4598

STEVEN L. HIGHLANDER
PARTNER

INTERNET ADDRESS:
SHIGHLANDER@FULBRIGHT.COM

DIRECT DIAL: 512/536-3184

HOUSTON
WASHINGTON, D.C.
AUSTIN
SAN ANTONIO
DALLAS
NEW YORK
LOS ANGELES
MINNEAPOLIS
LONDON
HONG KONG

RECEIVED

JAN 10 2001

TECH CENTER 1600/2900

December 21, 2000

FILE: MYOG:029US



CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, on the date below:

December 21, 2000
Date

Steven L. Highlander

Commissioner for Patents
Washington, DC 20231

RE: SN 09/061,417 "METHODS AND COMPOSITIONS FOR THERAPEUTIC INTERVENTION IN CARDIAC HYPERTROPHY" – By Eric N. Olson et al.
(UTSMC/DAL:548)

Commissioner:

Enclosed for filing in the above-referenced patent application is:

- (1) A Restriction Requirement to Office Action dated November 21, 2000; and
- (2) A return postcard to acknowledge receipt of these materials. Please date stamp and mail this postcard.

Should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Commissioner is authorized to deduct said fees from Fulbright & Jaworski L.L.P. Account No.: 50-1212/10017631/SLH.

Respectfully submitted,

Steven L. Highlander
Reg. No. 37,642


SLH/cpj
Encl.:



CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, DC 20231, on the date below:

Date December 21, 2000


Steven L. Highlander

GAU 1632

14
160
6-29-00
RECEIVED
JAN 10 2001
TECH CENTER 1600/2900

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Eric N. Olson et al.

Serial No.: 09/061,417

Filed: April 16, 1998

For: METHODS AND COMPOSITIONS FOR
THERAPEUTIC INTERVENTION IN
CARDIAC HYPERTROPHY

Group Art Unit: 1632

Examiner: Anne-Marie Baker, Ph.D.

Atty. Dkt. No.: MYOG:029US

RESPONSE TO RESTRICTION REQUIREMENT DATED MARCH 13, 2000

Commissioner for Patents
Washington, D.C. 20231


Sir:

This paper is submitted in response to the Restriction Requirement dated November 21, 2000 for which the date for response is **December 21, 2000**. No fees are believed due; however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be required for any reason relating to the enclosed materials, the Assistant Commissioner is authorized to deduct or credit said fees from or to Fulbright & Jaworski Deposit Account No. 50-1212/10017631/SLH.

In response to the restriction requirement which the Examiner imposed, Applicants elect, without traverse, to prosecute claims 1, 4 and 9, *i.e.*, the Group V claims.

The Examiner is invited to contact the undersigned attorney at (512) 536-3184 with any questions, comments or suggestions relating to the referenced patent application.

Respectfully submitted,



Steven L. Highlander
Reg. No. 37,642
Attorney for Applicant

FULBRIGHT & JAWORSKI
600 Congress Avenue
Suite 1900
Austin, Texas 78701
(512) 536-3184

Date: December 21, 2000